The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven ...

Kimberly-Clark is buying Kenvue, the maker of Tylenol, after months of controversy around whether the medicine is linked to autism.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

A £30 billion takeover shakes up the consumer health sector as Kimberly-Clark, the maker of Huggies nappies, prepares to ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

President Trump's health secretary said Tylenol should be used with caution during pregnancy, but solid data linking it to ...

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when ...

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive ...

Tylenol faces scrutiny over pregnancy use and autism links, despite scientific bodies finding no firm evidence. While ...

New research shows no causal link between Tylenol use during pregnancy and autism. Experts say acetaminophen remains safe for ...

One of the biggest mergers of the year, worth $49 billion, comes just weeks after the Trump administration linked the common ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...